The Mucolipidosis Collaborative Research Network (MCRN)Klein, Jennifer J.Elsevier BV2021DOI 10.1016/j.ymgme.2020.12.129
1236 Lancering MCRN: Betere Medicijnen Voor KinderenBohn Stafleu van LoghumBohn Stafleu van Loghum2008DOI 10.1007/bf03097471
The Medicines for Children Research Network (MCRN)Sam JonesElsevier Science2008DOI 10.1016/j.jnn.2007.12.007
Supporting MCRN Research Through Improving Clinical Trial Delivery by Hospital PharmaciesNorton, C.BMJ Publishing Group2011DOI 10.1136/adc.2011.211243.11
1125 The Fimp-Mcrn (Family Paediatricians Medicines for Children Research Network)Napoleone, ENature Publishing Group2010DOI 10.1203/00006450-201011001-01125
MCRN: A Multi-source Cross-modal Retrieval Network for remote sensingZhiqiang YuanElsevier BV2022DOI 10.1016/j.jag.2022.103071
Pharmacovigilance in Pediatric Age: The Role of Family Pediatricians- Medicines for Children Research Network (FP-MCRN)Ettore Napoleone Cristiana ScasserraOMICS Publishing Group2015DOI 10.4172/2329-6887.1000168
Improving the Evidence Base for Treatment of Juvenile Idiopathic Arthritis: the Challenge and Opportunity Facing the MCRN/ARC Paediatric Rheumatology Clinical Studies GroupThornton, J.Oxford University Press2008DOI 10.1093/rheumatology/ken055
Initial Results of MCRN 009: Phase 2 Study of an Accelerated Infusion Rate of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (MM).Stakiw, JulieElsevier2019DOI 10.1016/j.clml.2019.09.428
Excellence in Family Paediatricians: the FIMP-MCRN (Medicines for Children Research Network) becomes a member of ENPR-EMA (European Network of Paediatric Research at the European Medicines Agency)Ettore NapoleoneBioMed Central2011DOI 10.1186/1824-7288-37-7
Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN‐003/MYX.1 single arm phase II trialVenner, Christopher P.Wiley2021DOI 10.1002/ajh.26147
Myeloma Canada Research Network (MCRN) 001 Trial with Intravenous (IV) Busulfan + Melphalan (BuMel) as Enhanced Conditioning, followed by Lenalidomide (Len) Maintenance in Newly Diagnosed Multiple Myeloma (MM) Patients (Pts): First Results of Minimal Residual Disease (MRD) and Hevylite(TM) Chain (HLC) Assays at Day 100 Post Autologous Stem Cell Transplant (ASCT)Reece, D.Elsevier2015DOI 10.1016/j.clml.2015.07.190
